Celltex to study mesenchymal stem cells for coronavirus treatment

17 March 2020 (Last Updated March 17th, 2020 12:36)

Celltex Therapeutics has initiated talks with the US Food and Drug Administration (FDA) to conduct a study of adult, autologous mesenchymal stem cells (MSCs) for the treatment of Covid-19 symptoms.

Celltex to study mesenchymal stem cells for coronavirus treatment
Focal adhesions in human mesenchymal stem cells. Credit: Chun Yang, Hao Ma and Anouk Killaars, University of Colorado Boulder.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Celltex Therapeutics has initiated talks with the US Food and Drug Administration (FDA) to conduct a study of adult, autologous mesenchymal stem cells (MSCs) for the treatment of Covid-19 symptoms.

The company assessed the safety and efficacy of MSCs in people with injuries, pain and conditions associated with autoimmune, vascular and other diseases such as pneumonia.

Celltex, in alliance with the Texas A&M University Institute for Regenerative Medicine, evaluated MSCs in Covid-19 patients. Data from this study showed that intravenous administration of clinical-grade human MSCs led to improved functional outcomes.

The editorial titled ‘Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (Covid-19) – Induced Pneumonia’ was published in the Aging and Disease journal.

During the study, intravenous MSCs were found to be safe and effective in treating novel coronavirus patients with pneumonia. The therapy is said to have yielded encouraging data even in elderly patients with severe pneumonia.